NUCLEAR RADIOLOGY

I. Neshandar Asli MD¹. F. Tabeie PhD².

Pediatric Radiation Exposure from Diagnostic Nuclear Medicine Examinations in Tehran

Background/Objectives: As a part of a nationwide survey to estimate population exposure to radiation from diagnostic nuclear medicine in Iran, this paper presents the pediatric population radiation exposure due to nuclear medicine examinations in Tehran.

Patients and Methods: The effective dose equivalent, H_E , was used to calculate the collective effective dose in pediatric patients undergoing nuclear medicine procedures, and the corresponding data were obtained from thirty out of thirty seven active nuclear medicine departments in Tehran.

Results: Annually about 5.26% of nuclear medicine examinations were performed on patients under 15 years of age in Tehran. The most frequent was renal examinations (38.2%), followed by thyroid (27.4%) and bone (26.7%). The annual collective H_E for patients under 15 was 19.03 human-Sv, which contributed 3.96% to the collective H_E for all patients. The contribution of renal, bone and thyroid examinations to the pediatric collective H_E were 24.6%, 48.8% and 13.5% respectively. The mean effective dose equivalent per pediatric patient was 3.75 mSv.

Conclusion: Among the three most frequent examinations, the bone with a relative frequency of 27.4% constituted 48.8% of the collective $H_{E_{\rm c}}$ which was the highest absorbed dose per examination. The mean effective dose per examination for patients younger than 15 years was 67.9% of the adults.

Keywords: pediatrics, diagnostic nuclear medicine, radiation exposure

Introduction

Life on earth is constantly exposed to various forms of ionizing radiation from natural sources such as cosmic rays and natural radioactivity, as well as the ionizing radiation used in medicine. Ionizing radiation has valuable clinical usage in diagnostic radiology, nuclear medicine and radiotherapy. Diagnostic x-ray examinations constitute the largest source of man-made radiation exposure, ¹⁻⁸ however, the rapid expansion of diagnostic nuclear medicine procedures that involve the use of unsealed radiopharmaceuticals also requires assessment of the population exposures to this type of radiation. ⁹⁻²⁷

Given the significant benefits of properly conducted nuclear medicine procedures to pediatric patients, the main concern in radiation protection is reducing the exposures of children as far as possible. Therefore, the main purpose of this study was to identify the amount of pediatric population exposure during diagnostic nuclear medicine examinations.

The concept of "total body dose" or "whole body dose" has been employed by many investigators in evaluation of the risks of different nuclear medicine procedures. Although this concept may be useful for comparing the doses received from different procedures, it does not give an indication for the non-uniform distribution of radiopharmaceuticals throughout the body. ICRP (International Commission on Radiation Protection) has issued quantitative recommendations on patient exposure to nuclear medicine examinations which have been applied

1- Professor, Department of Nuclear Medicine, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2- Assistant Professor, Departments of Nuclear Medicine and medical physics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Corresponding Author: Isa Neshandar Asli Address: Department of Nuclear Medicine. Taleghani Hospital. Tehran, Iran. Tel: 009821-22402995 Fax: 009821-22403694 E-mail: isa neshandar@yahoo.com

Received January 22, 2005; Accepted after revision November 26, 2005.

Autumn 2005; 3: 35-39

PHOTO PAGE



¹Head of Iranian Society of Radiology

and evaluated in several studies. ⁹⁻²⁹ The "effective dose equivalent", H_E, was introduced by ICRP originally to protect workers occupationally exposed to radiation. ²⁸ At first, H_E was not meant for patients undergoing x-ray examinations or nuclear medicine procedures involving administration of radiopharmaceuticals. However, many investigators used H_E for comparing patient exposure from different diagnostic procedures subsequently. ⁹⁻²⁷

Patients and Methods

Comprehensive data including annual frequencies of nuclear medicine procedures, the type and amount of administered radiopharmaceuticals, and the age distribution of the examined patients were obtained from 33 of the 37 active nuclear medicine departments in Tehran, from April 2001 to March 2002. The effective dose equivalents (HE) of different radiopharmaceuticals are calculated based on absorbed doses per unit administered activities for different organs given in the ICRP publication 53, and tissue weighting factors given in the ICRP publication 26 .28,30 The effective dose per examination (mSv) for different radiopharmaceuticals are calculated by multiplying mean administered activity (MBq) and effective dose equivalent (mSv/MBq) for each examination in five age groups (<1, 1-5, 6-10 and <15 years). The collective effective dose equivalents (man-Sv) were calculated by multiplying the frequency of each examination in each age group by the corresponding effective dose per examination.

Results

The mean administered activity (MBq), effective dose equivalent (mSv/MBq), and effective dose per examination for 12 nuclear medicine procedures are given in Table 1. Some miscellaneous procedures using ^{99m}Tc-pertechnetate such as RBC scan, WBC scan, and parathyroid scan are summarized in one group as 'other' in the last row of Table 1. The mean value of effective dose equivalent per examination among all radiopharmaceuticals and age groups was 6.256 mSv with a range of 0.05-28.26 mSv.

Lung ventilation scan with 81m Kr had the lowest value for effective dose equivalent per examination (0.05-0.07 mSv), while tumor scan with 67 Ga-citrate showed the highest value (16.4-28.2 mSv). The



Fig~1. The contribution of each age groups to the total number of procedures and collective H_{E}



Fig 2. The contribution of each procedure to the total number of procedures and collective ${\sf H}_{\sf E}$.

Procedure	Radio-pharmaceutical		Mean A	Mean Administered	red		Effecti	Effective Dose Equivalent	quivaler	īt		Effectiv	re Dose	Effective Dose / Exam (mSv)	Ħ
			Activ	Activity (MBq)			H	H _E (mSv / MBq)	ЛBq)						
		~1	1-5	6-10	11-15	~1	1-5	6-10	10	11-15		~1	1-5	6-10	
Thyroid ¹	¹³¹ I INa	I	I	I	1.32	I	I			10.00000		I	I	I	
	^{99m} Tc TcO4	22.90	45.80	59.27	66.59	0.07300	0.04000	0 0.02500	500	0.01600		1.67	1.83	1.48	
Bone 9	99m Tc MDP,PYP	157.00	314.00	406.32	456.56	0.05000	-		500	0.01000	7		7.85	6.09	
Liver/Spleen ⁹	99m Tc SC	41.00	82.00	106.11	119.23	0.07600	0.04300		900	0.01900	3		3.53	3.08	
	^{99m} Tc IDA	40.38	80.75	104.49	117.41	0.15000	-		400	0.02900	6		5.65	4.60	
	99m Tc DTPA	88.08	176.15	227.94	256.12	0.03000	-		100	0.00780	2		2.99	2.51	
	99m Tc DMSA	27.15	54.30	70.26	78.95	0.06900	-	-	700	0.01900	1		2.17	1.90	
Lung perfusion 9	^{99m} Tc MAA	36.33	72.65	94.01	105.63	0.06900	-	-	500	0.01800	2		2.76	2.35	
ň	^{81m} Kr - Gas	437.50	875.00	1132.2	1272.25	0.00017	-	-	006	0.00004	0		0.08	0.06	
				თ											
Brain 9	^{99m} Tc TcO4	185.00	370.00	478.78	537.98	0.07300	0.04000	0 0.02500	500	0.01600	13	13.51	14.80	11.97	
MIBG 1	¹³¹ I INa	9.25	18.50	23.94	26.90	1.10000	0.61000	0 0.40000	000	0.26000	10	10.18	11.29	9.58	
Tumor 6	⁶⁷ Ga Citrate	35.33	70.65	91.42	102.73	0.79000	0.40000	0 0.25000	000	0.16000	27	27.91	28.26	22.86	
Other 9	^{99m} Tc TcO4	74.00	148.00	191.51	215.19	0.07300	0.04000	0 0.02500	500	0.01600	л		5.92	4.79	
able 2. Frequency of	examination, radiopharmac	euticals an	d the cor	respondin	g collective (effective dos	se for each d	iagnostic nu	ıclear mec	licine proc	edure on p	ediatric pati	tients.		
able 2. Frequency of Procedure	Table 2. Frequency of examination, radiopharmaceuticals and the corresponding collective effective dose for each diagnostic nuclear medicine procedure on pediatric patients Procedure Radiopharmaceutical Frequency of examinations Effective dose per examination (m Sv) Collective effective	euticals an cal F	d the con	respondin y of exa	and the corresponding collective Frequency of examinations	offective dos Effec	ive dose for each diagnostic nuclear medicine Effective dose per examination (m Sv)	iagnostic nu er examin	<u>iclear mec</u> ation (m	licine proc Sv)	edure on p Collec	re on pediatric patients. Collective effective dose (Man-mSv)	tients.	se (Man	
able 2. Frequency of Procedure	[.] examination, radiopharmaco Radiopharmaceuti	euticals and cal Fr <1	id the corre requency 1 1-5	responding ry of exam 5 6-10	g collective e minations 0 11-15	effective dos Effec <1	se for each d tive dose p 1-5	iagnostic nuc er examina 6-10	ation (m) 11	nedicine proc (m Sv) 11-15	edure on p Collec <1	ediatric pati t ive effec 1-5	tients. ctive do	ose (Man 6-10	
able 2. Frequency of Procedure Thyroid	examination, radiopharmace Radiopharmaceuti	euticals anc cal Fr <1 0	id the corr requence 1 1-5	respondiny y of exa 5 6-1	g collective (minations 0 11-15 18	effective dos	se for each d tive dose p 1-5	iagnostic nu er examin 6-1(<u>ation (m</u>) 11	<u>inedicine proc</u> m Sv) 11-15 13.16	edure on p Collec <1 0.00	ediatric pati t ive effec 1-5 0.00	tients.	ose (Man 6-10 0.00	
iable 2. Frequency of Procedure Thyroid	examination, radiopharmace Radiopharmaceuti ¹³¹ I INa ^{99m} Tc TcO4	euticals and cal Fre <1 335	id the corre requency 1 1-5) 0 5 359	responding :y of exan 5 6-1() 0 388	<u>a collective</u> minations 0 11-15 18 3 519	affective do: Effec <1 - 1.67	<u>se for each d</u> tive dose p 1-5 1.83	iagnostic nu er examina 6-10 	<u>ation (m</u> 111)	<u>adicine proc</u> n Sv) 1-15 13.16 1.07	edure on p Collec <1 0.00 559.45	ediatric pati t ive effec 1-5 0.00 656.97	tients. ctive do:	lose (Man 6-10 0.00 574.24	
Thyroid	examination, radiopharmace Radiopharmaceuti 131 I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP	<u>euticals and</u> cal Fr 2 335	Id the corre requency 1 1-5 0 0 15 359 15 359 17 212	responding :y of exan 5 6-1() 0 9 388 2 434	<u>a collective (</u> minations 0 11-15 18 3 519 4 917	affective do: Effec -1 1.67 7.85	<u>se for each d</u> tive dose p 1-5 - 1.83 7.85	iagnostic nu er examina 6-10 - 1.48 6.09	iclear mec ation (m 11 12 3 1 3 1 4 4	<u>edicine proc</u> m Sv) [1-15 [13.16 1.07 4.57	edure on p Collec <1 0.00 559.45 792.85	ediatric pat t ive effec 1-5 656.97 1664.20	tients. ctive do: 0 26	lose (Man 6-10 0.00 574.24 2643.06	
'able 2. Frequency of Procedure Thyroid Bone Liver/Spleen	^r examination, radiopharmace Radiopharmaceuti ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc SC	euticals and cal Fr 0 333 100	Image: definition Image: definition interpretation 1 1-9 1 1-9 0 0 0 0 55 359 359 11 211 211 11 211 211	respondin ry of exa 5 6-1 5 6-1 9 38 9 38 2 43 7 7	<u>3 collective</u> minations 0 11-15 18 3 519 3 519 4 917 9	sffective dos Effec <1 1.67 7.85 3.12	<u>se for each d</u> tive dose p 1-5 1.83 7.85 3.53	iagnostic nu er examina 6-10 1.48 6.09 3.08	ation (m 0 11 13 12 3 1 4 4 4 4	edicine proc m Sv) [11-15 [13.16 1.07 1.07 4.57 2.27	edure on p Collec <1 0.00 559.45 792.85 0.00	<u>ediatric patie</u> t ive effect 1-5 0.00 656.97 1664.20 17.65	tijents. ctive do: 7 5; 0 26	ose (Man 6-10 0.00 574.24 2643.06 21.56	
'able 2. Frequency of Procedure Thyroid Bone Liver/Spleen Biliary	examination, radiopharmace Radiopharmaceution ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc SC ^{99m} Tc IDA	euticals and cal Fr 0 335 101 103 34	d the correct requency 1 1-5 5 355 35 352 31 212 31 212 31 5 32 5 35 352 35 352 35 352 36 352 37 352 38 352 39 353 35 352 35 352 36 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37 352 37	responding responding ryy of exar 5 6-11 5 6-10 9 388 9 388 9 388 2 434 7 7 7 12	<u>a collective (</u> minations 0 11-15 18 3 519 4 917 4 917 19	effective dos Effec <1 1.67 7.85 3.12 6.06	<u>se for each d</u> tive dose p 1-5 1.83 7.85 3.53 5.65	iagnostic nu er examina 6-10 1.48 6.09 3.08 4.66	Inclear mee ation (m 11 11 13 13 1 1 1 2 3 1 3 1 3 1 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3	edicine proc m Sv) [1-15 [13.16 1.07 1.07 4.57 2.27 3.40	edure on p Collec <1 0.00 559.45 792.85 0.00 206.04	<u>ediatric pat</u> tive effec 1-5 0.00 656.97 1664.20 17.65 84.75	tients. ctive do: 7 5' 0 26	ose (Man 6-10 0.00 574.24 5643.06 21.56 55.92	
'able 2. Frequency of Procedure Thyroid Bone Liver/Spleen Biliary Renal	examination, radiopharmace Radiopharmaceuti ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc SC ^{99m} Tc IDA ^{99m} Tc DTPA	euticals and cal Fr 335 101 34 85	interpretation	responding responding yy of exan 5 6-1(9 388 9 10 9 388 9 10 9 10 9 10 9 10 9 10 9 10 9 10 9 10	<u>a collective</u> (<u>minations</u> 0 11-15 18 3 519 18 4 917 9 4 917 19 19	sflective do: Effec <1 7.85 7.85 3.12 6.06 2.64	<u>se for each d</u> tive dose p 1-5 1.83 7.85 3.53 5.65 2.99	iagnostic nu er examina 6-10 - 1.48 6.09 3.08 4.66 2.51	Inclear mediation (m 11 11 12 13 14 15 16 17 18 19 14 15 16 17 17 18 19 12 13 14 15 16 17 18 17 18 19 10 11 12 12 12	edicine proc m Se) [1-15 [13.16 1.07 4.57 4.57 2.27 3.40 2.00	edure on p Collec <1 0.00 559.45 792.85 0.00 206.04 224.40	<u>ediatric patii</u> tive effect 1-5 0.00 656.97 1664.20 17.65 84.75 84.75	tients. ctive do ctive do ctive do c c c c c c c c c c c c c c c c tive c c c c c c c c c c c c c c c c c c c	lose (Man 6-10 0.00 574.24 2643.06 21.56 21.56 55.92 276.10	
able 2. Frequency of Procedure Thyroid Bone Liver/Spleen Biliary Renal	i examination, radiopharmace Radiopharmaceuti ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc SC ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DMSA	euticals and cal Fre cal Fre 3355 101 101 34 85	$\begin{array}{c c} {\rm id\ the\ corre}\\ {\rm \ddot{r}equency}\\ {\rm \dot{r}equency}\\ {\rm 1 \ 1-5}\\ {\rm 359}\\ {\rm 359}\\ {\rm 359}\\ {\rm 359}\\ {\rm 359}\\ {\rm 1 \ 212}\\ {\rm 1 \ 212}\\ {\rm 1 \ 5}\\ {\rm 5 \ 121}\\ {\rm 15 \ 121} \end{array}$	responding y of exar y o 388 y o 388 y o 388 y o 10 y o 388 y o 12 y o 1	<u>a collective (</u> minations 0 11-15 18 3 519 3 519 3 519 4 917 9 19 19 19 19 230	=ffective dos Effec - - 1.67 7.85 3.12 6.06 2.64 1.87	<u>se for each d</u> tive dose p 1-5 - 1.83 7.85 3.53 5.65 2.99 2.17	iagnostic n. er examin - 1.48 3.08 4.66 2.51 1.90	Image: clear medic	edicine proc m Sv) 11-15 13.16 1.07 4.57 2.27 2.27 3.40 2.00 1.50	edure on p Collec <1 0.00 559.45 792.85 0.00 206.04 224.40 224.40	ediatric patii tive effect 1-5 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90	tients. ctive do: 0 26 0 27 0 26 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	lose (Man 6-10 0.00 574.24 2643.06 21.56 21.56 25.92 276.10 868.30	
able 2. Frequency of Procedure Thyroid Bone Liver/Spleen Biliary Renal Lung perfusion	rexamination, radiopharmace Radiopharmaceuti ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc MDP, ^{99m} Tc IDA ^{99m} Tc DTPA ^{99m} Tc DMSA ^{99m} Tc DMSA	euticals and cal Fr 0 33: 10: 34 8557(0	$\begin{array}{c c} \text{id the corr}\\ \hline \textbf{requenc}\\ 1 & 1-1\\ $	respondin respondin 5 6-1 9 38 9 38 9 38 7 7 7 7 11 11 11 11 11 6	<u>a collective (</u> minations 0 11-15 0 11-15 18 3 519 3 519 3 519 9 19 4 917 9 19 19 19 0 230 6	Effective dos Effect <1	<u>se for each d</u> 1-5 1.83 7.85 3.53 5.65 2.99 2.17	iagnostic nuc er examina - 1.48 6.09 3.08 4.66 2.51 1.90 2.35	$\begin{array}{c} \underline{\text{iclear med}}\\ \textbf{ation (m)}\\ \textbf{0}\\ 11\\ 1\\ 3\\ 1\\ 1\\ 3\\ 2\\ 3\\ 2\\ 1\\ 1\\ 3\\ 2\\ 1\\ 1\\ 1\\ 1\\ 1\end{array}$	adicine proc n Sv) 1-15 1.07 1.07 2.27 2.27 2.27 3.40 2.00 1.50	edure on p Collec <1 0.00 559.45 792.85 0.00 206.04 224.40 224.40 0.00	ediatric pati tive effec 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90 19.32	tients. 7 5'' 0 26 0 2 1 1	55 .92 574.24 643.06 21.56 21.56 25.92 276.10 368.30 14.10	
Table 2. Frequency of Procedure Thyroid Bone Liver/Spleen Biliary Renal Lung perfusion Lung Ventilation	examination, radiopharmaceutia Radiopharmaceutia ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc IDA ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DMSA ^{99m} Tc MAA ^{81m} Kr - Gas	euticals and cal Fi 33 10 34 577 0 0	$\begin{array}{c c} & d & decorr \\ \hline requence \\ 1 & 1 \\ 1 & 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 21 \\ 1 \\ 21 \\ 1 \\ 21 \\ 1 \\ $	respondin respondin 5 6-1 0 9 9 9 9 9 9 9 9	<u>a collective</u> (<u>minations</u> 0 11-15 18 3 519 18 9 19 19 19 230 275 6 2	sflective dos Effec <1 - 1.67 7.85 3.12 6.06 2.64 1.87 2.51	<u>se for each d</u> tive dose p 1-5 1.83 7.85 3.53 5.65 2.99 2.17 2.17 2.76	iagnostic nuc er examina 6-10 - 1.48 6.09 3.08 4.66 2.51 1.90 2.35 0.06	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	edicine proc n Sv) [1-15 13.16 1.07 4.57 2.27 2.27 3.40 2.00 1.50 1.50 1.50 1.90 0.05	edure on p Collec <1 0.00 559.45 792.85 0.00 206.04 224.40 224.40 0.00 0.00 0.00	ediatric patitive effec 1-5 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90 19.32 0.00	tients. 7 5 0 26 0 8	6-10 0.00 674.24 643.06 21.56 21.56 21.56 255.92 276.10 268.30 0.12	
Table 2. Frequency of Procedure Thyroid Bone Liver/Spleen Biliary Renal Lung perfusion Lung Ventilation Brain	examination, radiopharmaceutia Radiopharmaceutia ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DMSA ^{99m} Tc MAA ^{81m} Kr - Gas ^{99m} Tc TcO4	cal euticals an 57 6 6 6 7 7 7 8 8 7 7 7 7 7 7 7 7 7 7 7 7 7	$\begin{array}{c c} & \text{id the corr} \\ \hline requence \\ 1 & 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	respondin 5 6-1 5 6-1 9 9 388 7 7 7 12 11 110 6 45 2 43 7 7 7 2 43 7 7 7 2 43 7 7 7 2 43 7 7 7 2 43 2 43 2 43 2 2 43 2 2 43 2 2 43 2 2 43 2 2 2 43 2 2 2 43 2 2 2 43 2 2 2 43 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	<u>a collective</u> (<u>minations</u> 0 11-15 18 3 519 3 519 19 19 19 19 230 7 237 5 6 4 4	<u>effective dos</u> <u>Effec</u> - 1.67 7.85 3.12 6.06 2.64 1.87 2.51 0.07	<u>se for each di</u> 1-5 1.83 7.85 3.53 5.65 2.99 2.17 2.76 0.08	iagnostic n. er examin - 1.48 6.09 3.08 4.66 2.51 1.90 2.51 1.90 2.35 0.00	$\begin{array}{c} \text{Iclear mea} \\ \text{ation (m)} \\ 111 \\ 12 \\ 13 \\ 1 \\ 13 \\ 1 \\ 13 \\ 2 \\ 3 \\ 2 \\ 3 \\ 2 \\ 1 \\ 2 \\ 3 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1 \\ 2 \\ 1 \\ 1$	licine proc Sv) -15 -15 -17 -17 -17 -17 -17 -17 -17 -17	edure on p Collec <1 0.00 559.45 792.85 0.00 2206.04 224.40 224.40 0.00 0.00 0.00	ediatric pati tive effec 1.5 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90 19.32 0.00 14.80	tients. 7 5: 0 26 0 8: 1	ose (Man 6-10 0.00 574.24 643.06 21.56 21.56 255.92 276.10 276.10 868.30 868.30 14.10 0.12 0.12	
Table 2. Frequency of Procedure Procedure Thyroid Thyroid Bone Liver/Spleen Biliary Renal Lung perfusion Lung Ventilation Brain MIBG	 examination, radiopharmaceutia I INa ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DMSA ^{99m} Tc MAA ^{81m} Kr - Gas ^{99m} Tc TcO4 ¹³¹ I INa 	euticals and cal F 33 10 57 57 0 0 0	$\begin{array}{c c} & \text{id the correct} \\ \hline \mathbf{requency} \\ 1 & 1-5 \\ 1 & 1-5 \\ 1 & 1-5 \\ 1 & 1-5 \\ 1 & 15 \\ 1 & 11 \\ 1 & 15$	respondin 5 6-1 5 6-1 9 38 3 1 1 1 1 1 1 1 1 1 1	$\begin{array}{c} \begin{array}{c} \text{g collective } \epsilon \\ \hline \textbf{minations} \\ 0 & 11-15 \\ 18 \\ 3 & 519 \\ 3 & 519 \\ 3 & 519 \\ 19 \\ 19 \\ 19 \\ 19 \\ 19 \\ 19 \\ 230 \\ 7 & 275 \\ 6 \\ 6 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \end{array}$	effective dos Effect <1	se for each di 1-5 1.83 7.85 3.53 5.65 2.99 2.17 2.76 0.08 11.29	iagnostic nuc er examina 6-10 - 1.48 6.09 3.08 4.66 2.51 1.90 2.35 0.06) 11.97 9.58	Image: clear mediation (model 11 12 13 14 15 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 4 5 1 2 3 5 1 2 7 8 6 0 7 8 6 7 8 6 7 8 6 7 8 6 7 8 6 7 8 6 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8	edicine proc II Sv II 1 II 1 II 1 I 1 1 1 1 1 1 1 1	edure on p Collec <1 0.00 559.45 792.85 0.00 206.04 224.40 224.40 0.00 0.00 0.00 0.00	ediatric pati tive effec 1-5 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90 1019.90 19.32 0.00 14.80	tients. 0 26 0 26 0 27 57 20 1 1 2 7	ose (Man 6-10 0.00 574.24 5643.06 21.56 21.56 21.56 21.56 21.56 21.6 21.6 10 868.30 0.12 0.12 23.94 76.64	
Table 2. Frequency of Procedure Procedure Thyroid Thyroid Bone Liver/Spleen Biliary Renal Lung perfusion Lung Ventilation Brain MIBG Tumor	rexamination, radiopharmaceutia Radiopharmaceutia ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc MDP,PYP ^{99m} Tc MDP, ^{99m} Tc IDA ^{99m} Tc DTPA ^{99m} Tc DMSA ^{99m} Tc DMSA ^{81m} Kr - Gas ^{99m} Tc TcO4 ¹³¹ I INa ⁶⁷ Ga Citrate	euticals and cal F 0 0 10 10 33 34 57 57 57 0 0 0	$\begin{array}{c c} \text{id the corr}\\ \hline requence\\ 1 & 1-1\\ 1 $	respondin respondin 5 6-1 9 9 38 9 9 38 9 9 38 9 9 38 9 9 38 7 7 7 7 7 7 7 7 7 7 7 2 43 7 7 7 2 43 7 2 43 8 8 8 8 8 8 8 8 8 8 8 8	<u>a collective</u> <u>minations</u> 0 11-15 0 11-15 18 3 519 4 917 9 19 19 19 19 230 7 275 6 4 2 2 4 5 19 19 19 19 19 19 19 19 19 19	Effective dos Effect - - 1.67 7.85 3.12 6.06 2.64 1.87 2.51 0.07 13.51 10.18 27.91	se for each di 1-5 - 1.83 7.85 3.53 5.65 2.99 2.17 2.17 2.17 2.76 0.08 11.80 3 11.29	iagnostic nuc er examina 6-10 - 1.48 6.09 3.08 4.66 2.51 1.90 2.35 0.06 0.11.97 9 9.58	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	n Sv) 11-15 11-15 13.16 1.07 4.57 2.27 3.40 2.00 1.50 1.50 1.50 1.50 1.50 1.50 1.6 1.90 1.6 8.61 6.99 16.44	edure on p Collec <1	ediatric pati 1-5 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90 1019.90 19.32 0.00 14.80 203.22	tijents. ctive do: 0 26 0 80 1 1	ose (Man 6-10 0.00 574.24 2643.06 21.56 55.92 276.10 868.30 14.10 0.12 23.94 76.64 114.30	
Table 2. Frequency of Procedure Procedure Thyroid Bone Liver/Spleen Biliary Renal Lung perfusion Lung Ventilation Brain MIBG Tumor Other	examination, radiopharmace Radiopharmaceutii ¹³¹ I INa ^{99m} Tc TcO4 ^{99m} Tc TcO4 ^{99m} Tc IDA ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DTPA ^{99m} Tc DMSA ^{99m} Tc DMSA ^{81m} Kr - Gas ^{99m} Tc TcO4 ¹³¹ I INa ⁶⁷ Ga Citrate ^{99m} Tc TcO4	euticals and cal Fr 33: 10: 10: 10: 10: 10: 10: 10: 10: 10: 57(0 0 0 0 0 34: 57(0 0 0 34: 34: 34: 34: 34: 34: 34: 34: 34: 34:	Image: matrix of the constraints Trequenc; 1 $1 - 5$ 1 $1 - 5$ 1 212 1 212 1 212 1 5 1 5 1 212 1 5 1 15 4 155 12 70 470 470 70 470 70 470 70 127 7 77 1 112 1 1	responding respon	$\begin{array}{c} \begin{array}{c} \text{g collective } \epsilon \\ \textbf{minations} \\ 0 & 11-15 \\ 18 \\ 3 & 519 \\ 19 \\ 19 \\ 19 \\ 19 \\ 19 \\ 230 \\ 7 & 275 \\ 6 \\ 2 \\ 2 \\ 2 \\ 4 \\ 4 \\ 2 \\ 2 \\ 2 \\ 92 \end{array}$	sffective dos Effec - 1.67 7.85 3.12 6.06 2.64 1.87 2.51 1.3.51 10.18 27.91 5.40	se for each d tive dose p 1-5 - 1.83 7.85 3.53 5.65 2.99 2.17 2.17 2.76 0.08 1.4.8(1.4.8(1.4.8(1.4.8(1.4.8(1.25) 3.11.25 1.28,2()))))))))))))))))))))))))))))))))))	iagnostic nu er examina - - 1.48 6.09 3.08 4.66 2.51 1.90 2.35 0.06 111.97 9 9.58 5 22.86	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	edicine proc m Sv) 11-15 13.16 1.07 4.57 2.27 2.27 2.27 3.40 2.00 1.50 1.50 1.90	edure on p Collec <1 0.00 559.45 792.85 0.00 226.04 224.40 224.40 0.00 0.00 0.00 0.00 0.	ediatric pati tive effect 1-5 0.00 656.97 1664.20 17.65 84.75 361.79 1019.90 1019.90 19.32 0.00 14.80 203.22 56.52	tients. ctive do 0 26 0 26 0 80 1 2 2 1 2 4	lose (Man 6-10 0.00 574.24 2643.06 21.56 21.56 25.92 276.10 868.30 14.10 0.12 23.94 76.64 714.30 455.05	

frequency of procedures using each radiopharmaceutical and their corresponding collective effective dose for all age groups are given in Table 2. The total number of examinations and the collective effective dose for each age group are also presented in the last row of Table 2.

A total of 6055 diagnostic nuclear medicine examinations were performed on pediatric patients in Tehran with a collective effective dose of 19.03 man-Sv, between April 2001 to March 2002. The mean effective dose equivalent per pediatric patient was estimated 3.75 mSv. During the study period, 5.26% of the annual nuclear medicine examinations were performed on patients under 15 years of age in Tehran, which constituted 3.96% of the collective HE for all patients. The relative frequency and collective effective dose for each procedure are given in Figure 1. The relative frequency of renal nuclear examinations was 38.2% followed by bone (27.4%) and thyroid (26.7%). Renal, bone, and thyroid examinations contributed 24.6%, 48.8% and 13.5% to the pediatric collective HE, respectively.

The total number of procedures and their corresponding collective effective dose for each age group are given in Figure 1. The <1 age group had the lowest number of procedures and collective H_E (19.1% and 15.9% respectively), whereas the 10-15 age group had the highest values (34.6% and 33.7%, respectively).

Discussion

Because nuclear medicine is highly useful in urologic problems in pediatric patients, this paper clearly shows (Figure 2) the highest relative frequency for renal scans. Since the prevalence of urinary infections is a relatively common pediatric disease and regarding the values of DMSA renal scan in evaluation of renal parenchyma, the incidence of this scan is highest among the scintigraphic renal studies. The contribution of renal, bone and thyroid examinations to the total number of examinations are calculated to be 38.2%, 27.4% and 26.7% respectively. However, among the three most frequent examinations, bone with a relative frequency of 27.4% contributes 48.8% to the collective H_E which reflects the higher absorbed dose per examination for this procedure.

The mean effective dose per examination for patients younger than 15 years of age was 67.9% of the adults, which is in agreement with the requirements of radiation burden in children as compared to adults.¹⁸

Our data regarding the total diagnostic nuclear medicine procedures (5.26%), collective H_E (3.96%) and mean effective dose per patient (3.75 mSv) in the pediatric patients of Tehran resemble the findings of a study performed on Czech pediatric population in 1995. ¹⁸

Acknowledgment

The authors wish to thank the members of Iranian Society of Nuclear Medicine for their kind support of this national study.

References

- 1. UNSCEAR: 1977 Report to General Assembly, with annexes: Sources and effects of ionizing radiation. United Nations, New York, 1977.
- Shrimpton PC, Wall BF, Hart D. Diagnostic medical exposures in the U.K. Appl. Radiat. Isot. 1999; 50: 261-269.
- Shrimpton PC, Wall BF. The increasing importance of X-ray computed tomography as a source of medical exposure. Radiat. Prot. Dosim. 1995; 57: 413-415.
- Hart D, Hillier MC, Wall BF, Shrimpton PC, Bungay D. Doses to patients from medical X-ray examinations in the U.K.-1995 review. Chilton, NRPB-R289. 1996;SO. London.
- Hughes JS and O`riordan MC. Radiation exposure of the U.K. population-1993 review. Chilton, NRPB-R263. 1993; SO. London.
- Li LB, Wang JP, Yu XR, He SS, Yu FH, Ding CH. Medical radiation usage and exposures from medical X-ray diagnosis in Shandong province of China. Radiat. Prot. Dosimetry. 2001; 93: 261-266.
- Mettler FA, Davis M, Kelsy CA, Rosenberg R,Williams A. Analytical modeling of worldwide medical radiation use. Health Physics. 1987; 52: 133-141
- Brugmans JP, Wilhelmina CA, Geleijns j, Lembrechts j. Population exposure to diagnostic use of ionizing radiation in the Netherlands. Health Phys.,2002; 82; 500-509.
- Mohammadi H, Tabeie F Saghari M. Trends of population radiation absorbed dose from diagnostic nuclear medicine procedures in Iran: 1985-1989. Health Physics. 1995; 68: 503-508.
- Garacini S , Roncari G. Effective radiation dose to patient and to general population from nuclear medicine procedures: Variations in last twenty-years period. Quart. J. Nucl. Med. , 1995; 39: 99-104.
- Mettler FA, Christie JH, Williams AG ,Moseley RD. Population characteristics and absorbed dose to the population from nuclear medicine: United States-1982. Health Phys. 1986; 50:619-628.
- Poppitz R. Radiation risk to patients in diagnostic nuclear medicine in Bulgaria, 1980. Radiobiol. Radiother. 1983; 24: 131-141.
- Poppitz R. Patient exposure and radiation risk in Bulgarian diagnostic nuclear medicine. I. Survey of diagnostic nuclear medicine procedures in Bulgaria in 1980. Nuklearmedizin. 1982; 21: 85-91.

- Poppitz R. Patient exposure and radiation risk in Bulgarian diagnostic nuclear medicine. II. Somatically effective dose equivalents to the patients and assessment of risk. Nuklearmedizin. 1982; 21: 92-98.
- Huda W , Gordon K. Nuclear medicine staff and patient doses in Manitoba (1981-1985). Health Phys. 1989; 56: 277-285.
- Reiners C. Radiation exposure in diagnostic nuclear medicine: risk comparison on the basis of effective doses. Nuklearmedizin.1993; 32:47-51
- Overbeek F, Pauwels EK, Broerse JJ. Carcinogenetic risk in diagnostic nuclear medicine: biological and epidemiological considerations. Eur. J. Nucl. Med. 1994; 21: 997-1012.
- Hausak V, Petrova K, Prouza Z ,Myslivecek M. Medical radiation exposure of the Czech republic pediatric population due to diagnostic nuclear medicine. Nucl. Med. Rev. Cent. East Eur. 2000; 3: 143-147.
- Ftacnikova S ,Ragan P. Radiation dose to the population of Slovac republic from diagnostic nuclear medicine. Health Physics. 1995; 69: 16-20.
- Reiners C and Sonnenschein W. Radiation exposure from diagnostic nuclear medicine in Germany 1992 (the former federal republic). Nuklearmedizin. 1994; 33: 254-262.
- Papadopoulos G and Okkalides D. Dose tom patients through nuclear medicine procedures in a department in northern Greece. Eur. J. Nucl. Med. 1990; 17: 212-215.

- Beentjes LB ,Timmerman CW. Age and sex specific population doses(SED and GSD) due to nuclear medicine procedures in the Netherlands.Nucl. Med Biol., 1990; 17: 261-268.
- 23. Robertson JS. Radiation absorbed dose calculations in diagnostic nuclear medicine. Int. J. Appl. Radiat. Isot. 1982; 33: 981-990.
- Ftacnikova S , Ragan P. Radiation dose to the population of Slovac republic from diagnostic nuclear medicine. Health Physics. 1995; 69: 16-20.
- Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in the Netherlands. Health Physics. 1988; 54: 287-291.
- Johansson L, Mattsson S, Nosslin B , Svegborn SL. Effective dose from radiopharmaceuticals. Eur. J. Nucl. Med. 1992; 19: 33-938.
- International Commission on Radiological Protection, ICRP. Recommendations of the ICRP, ICRP publication 26. Annals of the ICRP. Pergamon Oxford. 1977.
- International Commission on Radiological Protection, ICRP. Recommendations of the ICRP, ICRP publication 60. Annals of the ICRP. Pergamon Oxford. 1991.
- International Commission on Radiological Protection, ICRP. Radiation dose to patients from radiopharmaceuticals. ICRP publication 60. Annals of the ICRP. Pergamon Oxford. 1988.